Burden on patients: Insurance benefit design’s impact on patient access to medicines

Allyson Funk   |     June 30, 2016   |   SHARE THIS

ABC-logo.pngLast week, we looked at access to medicines in health insurance exchanges for HIV/AIDS, oncology, cystic fibrosis, mental health and multiple sclerosis. The analysis by Avalere Health presents data on access to medications for chronic conditions in exchange plans.


Today, we’re looking at five more conditions and how insurance benefit design – and practices like utilization management – can be a hurdle to patients with chronic conditions accessing the medicines they need. Utilization management can mean prior authorization, where your health care professional has to get approval from your insurance company, or step therapy, where you might have to fail first on older or less personalized medicines before the medicine you are prescribed is covered.

  • Rheumatoid arthritis (RA) and other autoimmune diseases: In the majority of cases, when an RA drug is covered by an exchange plan, it is subject to utilization management.
  • Hepatitis: While coverage of hepatitis medicines improved, so did the use of utilization management for these medicines, up from 47 percent of the time in 2015 to 57 percent of the time in 2016.
  • Hyperlipidemia (high cholesterol): Utilization management is used for these medicines more than one third of the time in health insurance exchange plans.
  • Diabetes: Innovative diabetes medicines are more often placed on a non-preferred tier in health insurance exchange plans, and there is greater use of utilization management in exchange plans compared to employer plans.
  • Asthma and COPD: Utilization management for these medicines is low compared to other conditions, but remains higher than employer coverage.

Health insurance exchange coverage of medicines also varies greatly by state. Check out the map and state-specific fact sheets here.


Allyson Funk

Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience included leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.

Topics: Access, Diabetes, Affordable Care Act, Health Insurance, Burden on Patients, Asthma, Rheumatoid Arthritis, Access Better Coverage, High Cholesterol, Policy Solutions, Empower Consumers

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates